|Bid||341.50 x 800|
|Ask||342.50 x 3200|
|Day's range||328.02 - 346.10|
|52-week range||80.55 - 464.00|
|Beta (5Y monthly)||-1.22|
|PE ratio (TTM)||10.90|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||318.99|
Some Americans could prefer Moderna's booster because of perceptions that it offers higher efficacy.
Omicron happened this week. So as the medical world shifts to a yet-to-be-determined degree, a question comes to mind: Who will pay for all this? In fact, who’s paid for all the COVID fighting to date?
Dr. Tom Tsai, Senior Fellow at the Harvard Global Health Institute; Assistant Professor in Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health joins Yahoo Finance to discuss the latest with COVID-19 and the spread of the Omicron variant.